RoxyBond Gets US Advisory Panel OK For Abuse-Deterrent Claim Despite Excipient Concerns

 
• By Michael Cipriano

Members unanimously endorse product and mostly supported abuse-deterrent language; several panelists suggest warning about possible harmful effects of excipients by abusing product intravenously.

Opioid abuse epidemic concept

More from US FDA Performance Tracker

More from Regulatory Trackers